News & Media

Dec 08 / 2022

Hemostemix Issued “Your Fountain of Youth” Trademark by Cyprus
Nov 30 / 2022

Hemostemix Thanks Niem Malo, Beefstro’s Founder, for his ACP-01 Testimonial Interview
Nov 15 / 2022

Hemostemix Announces Advancements in its Automation of Production
Oct 26 / 2022

Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials
Oct 25 / 2022

Hemostemix Announces Presentation to the Emerging Growth Conference
Oct 19 / 2022

Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market
Oct 04 / 2022

Hemostemix Announces Exploring Clinical Trial Financing Alternatives
Sep 27 / 2022

Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to its Scientific Advisory Board
Sep 20 / 2022

Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board
Sep 16 / 2022

Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
Sep 15 / 2022

Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Sep 14 / 2022

Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to its Scientific Advisory Board
Sep 14 / 2022

Hemostemix Announces its Presentation to the Emerging Growth Conference
Sep 12 / 2022

Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
Aug 31 / 2022

Hemostemix Announces A Clarification
Aug 30 / 2022

Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections
Aug 22 / 2022

Hemostemix Announces Closing of UNIT Private Placement
Aug 19 / 2022

Hemostemix Announces Unit Private Placement
Aug 12 / 2022

Hemostemix Announces Closing of Second Tranche of UNIT Private Placement
Jun 27 / 2022

Dr. Fraser Henderson
Jun 16 / 2022

Hemostemix Announces the Incorporation of PreCerv Inc.
May 19 / 2022

Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations
May 19 / 2022

Hemostemix Announces Financing
May 16 / 2022

Hemostemix Announces Rick Groome as Special Advisor to the CEO
May 10 / 2022

Hemostemix Announces Its Intellectual Property is Back Home
Apr 25 / 2022

Hemostemix Announces Closing of $2,750,000
Apr 12 / 2022

Intellectual Property Due Diligence and Data Audit Completed
Mar 24 / 2022

Hemostemix Announces Settlement Agreement
Mar 03 / 2022

Interest Payment on Convertible Debenture
Mar 02 / 2022

Hemostemix Announces $2,750,000 Convertible Debenture
Mar 01 / 2022

Hemostemix Announces Stock Options Grant
Feb 28 / 2022

Hemostemix Announces Closing of UNIT Private Placement
Feb 14 / 2022

Your Fountain of Youth Trademarked by Hemostemix
Feb 02 / 2022

Hemostemix Announces Financing
Jan 21 / 2022

Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics
Jan 12 / 2022

Hemostemix to combine ACP-01 with Dr. James Shapiro’s Islet Cells to treat Type 1 Diabetes